Eikon Therapeutics, Inc. (EIKN) income statement
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$4.74−0.02 (-0.42%)
Close on Nov 20, 2026Market cap $256.74MP/E –Yield –
Eikon Therapeutics, Inc. financial ratios
See a number that looks wrong?